ストックスクリーナーアプリを入手
25.65
1.72%
-0.45
前日終値:
$26.10
開ける：
$25.58
24時間の取引高:
45.36M
Relative Volume:
0.72
時価総額：
$145.84B
収益：
$62.79B
当期純損益:
$9.84B
株価収益率:
14.95
EPS:
1.7156
ネットキャッシュフロー:
$10.38B
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+3.09%
6か月 パフォーマンス:
+1.14%
1年 パフォーマンス:
-2.99%
1日の値動き範囲:
$25.51
$25.68
1週間の範囲:
$25.09
$26.31
52週間の値動き範囲:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.65 | 148.40B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,064.29 | 973.23B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
220.14 | 526.41B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.26 | 385.48B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.14 | 278.22B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.26 | 276.52B | 46.69B | 15.29B | 9.25B | 3.4329 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Quilter Plc Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Sector Gamma AS Increases Stake in Pfizer Inc. $PFE - MarketBeat
UniSuper Management Pty Ltd Increases Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Commerzbank Aktiengesellschaft FI Increases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Refines Vaccine Toolkit With Matrix M Deal And ViiV Exit - simplywall.st
The Best Stocks to Invest $40 in to Start the New Year Off Right - Finviz
The Best Stocks to Invest $40 in to Start the New Year Off Right - The Motley Fool
Pfizer Inc. $PFE Stock Position Lessened by Resona Asset Management Co. Ltd. - MarketBeat
Rakuten Investment Management Inc. Buys New Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Refocuses Portfolio With Matrix M Deal And ViiV Exit - simplywall.st
Lobbying Update: $2,810,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer (NYSE:PFE) Stock Price Down 1.7%Here's What Happened - MarketBeat
Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more - BioWorld MedTech
Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research - Benzinga
Pfizer’s New Autoimmune Candidate PF-08065010 Enters Phase 1: What Investors Should Watch - TipRanks
Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know - TipRanks
Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline - TipRanks
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview) (NYSE:PFE) - Seeking Alpha
Pfizer Inc. $PFE Shares Purchased by Teacher Retirement System of Texas - MarketBeat
Lockheed Martin Investment Management Co. Grows Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Position Raised by Strs Ohio - MarketBeat
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Pfizer (PFE) Valuation Check As Shares Recover Modestly From Longer Term Weakness - simplywall.st
Pfizer Target of Unusually High Options Trading (NYSE:PFE) - MarketBeat
Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress - TipRanks
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies - BioSpace
How Is The Market Feeling About Pfizer Inc? - Benzinga
Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap? - Finviz
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
Pfizer CEO Takes Aim at Kennedy Over Vaccines - The Wall Street Journal
Pfizer (NYSE:PFE) Shares Up 1.5%What's Next? - MarketBeat
The Bull Case For Pfizer (PFE) Could Change Following Novavax Matrix-M Adjuvant Licensing DealLearn Why - simplywall.st
Pfizer (PFE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Novavax Strikes Major Deal with Pfizer, Surge in Stock Likely - StocksToTrade
Pfizer Pockets $1.9B by Offloading Stake in HIV Drugs Company Majority Owned by GSK - MedCity News
(PFE.N) | Stock Price & Latest News - Reuters
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
Ex-Dividend Reminder: Albertsons Companies, Signet Jewelers and Pfizer - Nasdaq
Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M (NASDAQ:NVAX) - Seeking Alpha
Pfizer CEO on His Relationship With RFK Jr. - Yahoo Finance
Pfizer Inc. (NYSE:PFE) Declares $0.43 Quarterly Dividend - MarketBeat
Pfizer and Novavax ink $530m vaccine delivery licensing deal - Yahoo Finance
3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer - Finviz
Novavax inks license agreement with Pfizer - The Pharma Letter
Novavax signs licensing agreement with Pfizer for vaccine development - Reuters
GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare - BioSpectrum Asia
Pfizer Inc. - Britannica
Assessing Novavax (NVAX) Valuation After Pfizer Matrix M Licensing Deal - Yahoo Finance
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
3.65%
0.67%
大文字化:
|
ボリューム (24 時間):